Abbott Laboratories (NYSE:ABT) saw unusually-high trading volume on Thursday . Approximately 9,706,353 shares were traded during mid-day trading, a decline of 11% from the previous session’s volume of 10,877,903 shares.The stock last traded at $41.39 and had previously closed at $40.83.

ABT has been the subject of a number of recent analyst reports. BTIG Research restated a “buy” rating and issued a $45.00 target price on shares of Abbott Laboratories in a report on Wednesday, March 16th. Jefferies Group restated a “buy” rating and issued a $47.00 target price (up from $45.00) on shares of Abbott Laboratories in a report on Tuesday, March 15th. Leerink Swann boosted their target price on shares of Abbott Laboratories from $37.00 to $40.00 and gave the company a “market perform” rating in a report on Monday, March 28th. Zacks Investment Research upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $44.00 target price for the company in a report on Tuesday. Finally, Stifel Nicolaus boosted their target price on shares of Abbott Laboratories from $42.00 to $47.00 and gave the company a “buy” rating in a report on Monday, March 28th. Seven analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $46.40.

The company has a market capitalization of $61.54 billion and a price-to-earnings ratio of 25.79. The stock has a 50 day moving average price of $38.74 and a 200 day moving average price of $40.02.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Wednesday, April 20th. The healthcare product maker reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.02. The business earned $4.90 billion during the quarter, compared to analyst estimates of $4.77 billion. Abbott Laboratories’s revenue for the quarter was down .2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.47 EPS. Equities research analysts expect that Abbott Laboratories will post $2.20 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 15th. Stockholders of record on Friday, July 15th will be issued a $0.26 dividend. The ex-dividend date is Wednesday, July 13th. This represents a $1.04 dividend on an annualized basis and a dividend yield of 2.48%.

In other news, EVP Hubert L. Allen sold 3,400 shares of the company’s stock in a transaction dated Tuesday, June 28th. The stock was sold at an average price of $37.14, for a total value of $126,276.00. Following the transaction, the executive vice president now owns 91,857 shares in the company, valued at approximately $3,411,568.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

A number of institutional investors have recently added to or reduced their stakes in the company. Dowling & Yahnke LLC increased its position in Abbott Laboratories by 0.7% in the fourth quarter. Dowling & Yahnke LLC now owns 80,597 shares of the healthcare product maker’s stock worth $3,620,000 after buying an additional 589 shares in the last quarter. Spinnaker Trust increased its position in Abbott Laboratories by 0.4% in the fourth quarter. Spinnaker Trust now owns 26,559 shares of the healthcare product maker’s stock worth $1,193,000 after buying an additional 108 shares in the last quarter. Nationwide Fund Advisors increased its position in Abbott Laboratories by 4.5% in the fourth quarter. Nationwide Fund Advisors now owns 1,651,661 shares of the healthcare product maker’s stock worth $74,176,000 after buying an additional 70,731 shares in the last quarter. Investment Counselors of Maryland LLC increased its position in Abbott Laboratories by 0.5% in the fourth quarter. Investment Counselors of Maryland LLC now owns 27,260 shares of the healthcare product maker’s stock worth $1,224,000 after buying an additional 125 shares in the last quarter. Finally, Norris Perne & French LLP MI increased its position in Abbott Laboratories by 102.1% in the fourth quarter. Norris Perne & French LLP MI now owns 212,673 shares of the healthcare product maker’s stock worth $9,551,000 after buying an additional 107,417 shares in the last quarter.

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.